Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis

Ning Tang, Dan Lyu, Yan Zhang and Haiping Liu

Abstract

Background: Ovarian cancer is a prominent public health problem which affects people all around the world. Platinum-based chemotherapy is a common treatment for ovarian cancer, however, the effectiveness of chemotherapy varies from patient to patient. The excision repair cross complementation group 1 (ERCC1) protein may mediate chemotherapy resistance. A meta-analysis was conducted to explore whether platinum-based chemotherapy effectiveness could be attributed to the ERCC1 C19007T polymorphisms.

Methods: Seven major databases (EMBASE, Web of Science, Pubmed, Springer Link, Chinese National Knowledge Infrastructure (CNKI), EBSCO and Science Direct databases) were searched for eligible studies. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to evaluate the results.

Results: In this meta-analysis, 1169 subjects (425 non-responders and 744 responders) from 8 studies were included. The overall OR (C vs. T alleles) using random model was 1.07 (95% CI 0.75-1.52, \( P = 0.7 \)), which was not statistically significant. Moreover, there was no significant difference in the analysis by race.

Conclusion: There is no association between the ERCC1 C19007T polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer. The polymorphism did not have a significant impact on platinum-based chemotherapy in non-responders and responders.

Keywords: ERCC1 C19007T, Platinum-based chemotherapy, Ovarian cancer
in patients with epithelial ovarian cancer (EOC). On the other hand, Qi [11] reported that CC, CT and TT frequency in rs11615 was significantly different between responders and non-responders to platinum treatment in patients with EOC. Therefore, a comprehensive review of rs11615 in the responders and non-responders of EOC patients is required. In this study, we performed a meta-analysis of the published literature to assess the association between the ERCC1 protein expression and the response to platinum-based chemotherapy in patients with ovarian cancer.

Methods

Literature review

We searched the EMBASE, Web of Science, PubMed, Springer Link, Chinese National Knowledge Infrastructure (CNKI), EBSCO and Science Direct databases to identify the publications that reported the association between the excision repair cross-complementation group 1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer from March, 1980 to December, 2014. The key words for chemotherapy effectiveness, including outcome, response, resistance, etc. were complex; therefore, we used the keywords as follows: ‘ovarian cancer, excision repair cross-complementation group 1, polymorphism,’ ‘ovarian cancer, excision repair cross-complementation group 1, SNP’. ‘ovarian cancer, excision repair cross-complementation group 1, allele,’ ‘ovarian cancer, ERCC1, polymorphism,’ ‘ovarian cancer, ERCC1, SNP,’ ‘ovarian cancer, ERCC1, allele,’ ‘ovarian carcinoma, excision repair cross-complementation group 1, polymorphism,’ ‘ovarian carcinoma, excision repair cross-complementation group 1, SNP,’ ‘ovarian carcinoma, excision repair cross-complementation group 1, allele,’ ‘ovarian carcinoma, ERCC1, polymorphism,’ ‘ovarian carcinoma, ERCC1, SNP,’ ‘ovarian carcinoma, ERCC1, allele’.

The articles related to platinum-based chemotherapy effectiveness were manually extracted from the articles related to ovarian cancer therapy or other chemotherapy effectiveness. Responder and non-responder were chosen as the parameter in this study. Responder was defined as “complete response (disappearance of tumor, which was confirmed at 4 weeks) + partial response (30% decrease in tumor size, which was confirmed at 4 weeks). Stable disease or progressive disease was not included. Non-responder was defined as disease progression during platinum-based chemotherapy or recurrence during therapy or without completing the therapy. After excluding duplicates, titles and abstracts were reviewed. Studies were included if they: 1) were non-responder-responder studies, which comparing the difference between the non-responders and responders to the platinum-based chemotherapy in EOC; 2) reported genotype distribution in both non-responders and responders; 3) articles in English or Chinese with an English abstract. The studies were excluded if they were: 1) review articles; 2) not related to ovarian cancer; 3) animal or in vitro study; 4) not related to the association between ovarian cancer and polymorphism; 5) not related to ERCC1. The study selection process was summarized in Fig. 1.

Data extraction

For each study, the following information was extracted from the original articles: the name of the first author, the year of publication, country of origin, race of study population, genotype distributions for each polymorphism in both cases and controls, statistical characteristics of each study (sample size, gender and age distribution of cases and controls, \( P \) values for HWE evaluation), source of controls, and genotyping methods (Table 1).

Statistical analyses

Statistical analyses were conducted with Stata 13.0 (College Station, TX). Hardy-Weinberg Equilibrium (HWE) was performed in controls by asymptotic Pearson’s Chi-square test for each polymorphism in each study. The association between polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer was estimated with odds ratios (OR) and corresponding 95% confidence intervals (CIs). Between studies heterogeneity was tested using Q test and I² test, and the heterogeneity was considered significant if \( P \)-value was less than 0.05. Fixed-effects model was adopted when \( P \)-value was more than 0.05; otherwise random-effects model was used [12]. The publication bias was evaluated using Begg’s test, Egger’s test and Harbord’s test [13-15]. \( P < 0.05 \) was considered statistically significant.

Results

The characteristics of included studies

A total of 1220 articles were obtained from the literature search. As shown in Fig. 1, after excluding the duplicates, 689 abstracts were reviewed. A total of 15 research articles reporting the association of human ERCC1 gene polymorphisms and platinum-based chemotherapy effectiveness in ovarian cancer were identified. Seven articles were excluded after reviewing the full-text article because the polymorphism they studied didn’t appear in other articles, or they did not study chemotherapy effectiveness or they did not include the SNP distribution details. Finally, 8 studies from 8 articles were included in this analysis [10, 11, 16-21]. Six articles were published in English and two articles were published in Chinese. The SNP C19007T (rs11615) was studied. As shown in Table 1, the race of the study population included Asian and Caucasian. The pooled study population consisted
of 1169 subjects (425 non-responders and 744 responders). For example, Steffensen et al. [20] showed that 13 patients did not respond to the first line of treatment while 155 patients relapsed during the long-term treatment. Therefore, we chose the 155 patients as our subjects. The genotype and allele distributions of all polymorphisms were shown in Table 2. These genotype distributions in controls deviated from HWE. The location of each SNP was shown in Fig. 2 based on information from CNBI SNPs database.

Data synthesis by polymorphism

**ERCC1 C19007T polymorphism**

Eight case–control studies (425 non-responders and 744 responders) addressed the relationship between C19007T polymorphism and the effectiveness of chemotherapy in ovarian cancer. As shown in Table 3, the heterogeneity was significant ($P = 0.004$, $I^2 = 66.9\%$). The overall OR (C vs. T alleles) using random model was 1.07 (95% CI 0.75-1.52), $P = 0.7$. We also performed analysis using other models, but we did not identify any association (Table 3). The results show that there is no association between C19007T and platinum-based chemotherapy effectiveness in ovarian cancer. Subgroup analysis in allele comparison (C vs. T) was performed by race (Fig. 3). The race of the subjects in the studies from Steffensen et al. [17, 20], Bösmüller et al. [19], and Moxley et al. [10] was Caucasian; whereas the race of the subjects in the studies from Sokbom K et al. [18], Qi B et al. [11], and Yang et al. [21] was Asian. Furthermore, the same ethnicity (Chinese, studied by Qi B et al. [11] and Yang Shuying et al. [21]) or the same author (Steffensen et al. [17, 20]) showed different outcomes.

**Publication bias**

Begg’s test, Egger’s test, Harbord’s test and Begg’s funnel plot were calculated or plotted to detect the publication bias of the meta-analysis. The shapes of the funnel plot
for the ERCC1 C19007T polymorphism demonstrated an asymmetrical result in C vs. T model (Fig. 4). Nevertheless, Egger’s test ($P = 0.06$) and Harbord’s test ($P = 0.07$) indicated that the C vs. T model was not significantly different (Table 3). The publication bias was inconsistent using different tests. In a previous study, Begg’s method had a stronger statistical and discriminatory power [22].

**Discussion**

Platinum-based therapy is used in the treatment of several human cancers by damaging DNA in cancer cells at interphase. The NER pathway plays an important role in the repair of DNA damage [23, 24]. It has been reported that a number of single nucleotide polymorphisms (SNPs) of NER genes can alter the function of the respective genes, which might contribute to inter-individual variations of DNA repair capacity [6, 25]. Previous results suggest that DNA repair capacity might be influenced by genetic polymorphisms [26, 27]. The C19007T is a common polymorphism of ERCC1 gene and is associated with the effectiveness of platinum-based treatment in several types of cancers [28, 29]. Moxley et al. evaluated the association of ERCC1 and the response to platinum-based chemotherapy in ovarian cancer and found that negative ERCC1 expression was associated with a better response to platinum-based chemotherapy [10]. Their results proved that genetic variation in ERCC1 might contribute to impaired DNA repair capacity [10].

NER is the main mechanism by which platinum-induced damage is removed from DNA in mammalian cells. The recognition and incision step of the NER reaction requires the XPC (Xeroderma pigmentosum Table 1 Characteristics of the Studies Included in the Analysis

| Authors                  | Year of publication | Host ethnicity | Age (years Mean ± SD) | Samples (n) | Regimen of chemotherapy | Genotyping method |
|--------------------------|---------------------|----------------|----------------------|-------------|-------------------------|------------------|
| Sokbom K. et al. [18]    | 2009                | Asian          | No data              | 20          | Atinum-Taxane           | PCR-RFLP        |
| Steffensen K.D. et al. [20] | 2011               | Caucasian      | 54.92 ± 11.42        | 155         | Carboplatin and Paclitaxel | PCR-DNA chip    |
| Smith S. et al. [16]     | 2007                | Caucasian      | 66.9 ± 7.8           | 48          | carboplatin or cisplatin and paclitaxel | PCR-RFLP |
| Qi B. et al. [11]        | 2013                | Asian          | No data              | 73          | Platinum-Based, did not provide specific information | PCR-RFLP |
| Bösmüller H. et al. [19] | 2011                | Caucasian      | 59.7 ± 18.3          | 14          | Carboplatin-Taxane      | PCR-RFLP        |
| Steffensen K.D. et al. [17] | 2008               | Caucasian      | 61.1 ± 20            | 12          | Platinum-Based, did not provide specific information | PCR-DNA chip    |
| Moxley K.M. et al. [10]  | 2013                | Caucasian      | 64.89 ± 13.2         | 32          | Platinum-Based Chemotherapy | PCR-RFLP |
| Yang S. [21]             | 2011                | Asian          | 76.9 ± 17.6          | 71          | Cisplatin or Carboplatin and cyclophosphamide | PCR-RFLP |

**Table 2** Genotype and Allele Distribution of ERCC1 Polymorphisms in ovarian cancer Resistant and Responders

| SNP          | Study                  | C/C | C/T | T/T | C | T | C/C | C/T | T | Number (%) | Resistant | Responder | HWE | p |
|--------------|------------------------|-----|-----|-----|---|---|-----|-----|---|-------------|-----------|-----------|-----|---|
| ERCC1 C19007T| Sokbom K. et al. [18]  | 15  | 5   | 35  | 5 | 20| 16 | 4   | 56| 24| 50| 40| 0.09| 0.76 |
|              | Steffensen K.D. et al. [20] | 16  | 72  | 67  | 104| 206| 15 | 71  | 58| 101| 187| 155| 52| 144| 0.98| 0.32 |
|              | Smith S. et al. [16]    | 11  | 22  | 15  | 44 | 52| 23 | 60  | 45| 106| 150| 48| 27| 128| 0.15| 0.71 |
|              | Qi B. et al. [11]       | 38  | 26  | 9   | 102| 44 | 78 | 67  | 223| 71| 73| 33| 147| 67| 8.76| 0.003|
|              | Bösmüller H. et al. [19]| 6   | 5   | 3   | 17 | 11 | 7  | 9   | 11| 23| 31| 14| 34| 27| 66| 2.74| 0.1  |
|              | Steffensen K.D. et al. [17] | 3   | 7   | 2   | 13 | 11 | 12 | 34  | 42| 58| 118| 12| 12| 88| 88| 1.39| 0.24 |
|              | Moxley K.M. et al. [10] | 10  | 13  | 9   | 33 | 31 | 14 | 8   | 10| 36| 28| 32| 50| 32| 50| 8.04| 0.005|
|              | Yang S. [21]            | 28  | 31  | 12  | 87 | 55 | 70 | 67  | 1  | 207| 69| 71| 34| 138| 66| 11.98| 0.0005|

ERCC1 excision repair cross complementation group 1, HWE Hardy-Weinberg Equilibrium
complementation group C), XPA (Xeroderma pigmentosum complementation group A), RPA (Replication protein A), TFIIF (Transcription factor II Human), XPG (Xeroderma pigmentosum complementation group G) and the ERCC1–XPF (Xeroderma pigmentosum complementation group F) complex. XPC binds to the DNA, which alters its structure and allows the access of other repair factors. XPA, RPA, XPG and TFIIF attach to the distorted DNA and then the nucleases makes incisions on the damaged strand. ERCC1–XPF complex cuts 5′ of the lesion, whereas XPG cuts 3′. The excised DNA is replaced in a DNA-repair synthesis reaction that is catalyzed by DNA polymerase. XPA: Xeroderma pigmentosum complementation group A; XPC: Xeroderma pigmentosum complementation group C; XPF: Xeroderma pigmentosum complementation group F; XPG: Xeroderma pigmentosum complementation group G; RPA: Replication protein A; TFIIF: Transcription factor II Human.

C

ERCC1

C19007T

Fig. 2 The location, function and structure of ERCC1. a The location of RECC1. ERCC1, excision repair cross complementation group 1. b The function of ERCC1. XPC binds to DNA damage site (red circle), XPA, XPG, RPA and TFIIF attach to the distorted DNA and then nucleases make the incisions on the damaged strand. ERCC1–XPF complex cuts 5′ of the lesion, whereas XPG cuts 3′. The excised DNA is replaced in a DNA-repair synthesis reaction that is catalyzed by DNA polymerase. XPA: Xeroderma pigmentosum complementation group A; XPC: Xeroderma pigmentosum complementation group C; XPF: Xeroderma pigmentosum complementation group F; XPG: Xeroderma pigmentosum complementation group G; RPA: Replication protein A; TFIIF: Transcription factor II Human. c The structure of ERCC1. ERCC1 contains a central domain (from 96 amino acid residue to 214 amino acid residue) and an HhH2 domain (from 240 amino acid residue to 297 amino acid residue). The HhH2 domain is linked to XPF, whereas the central domain combines with DNA. HhH2, helix-hairpin-helix domain.
5′ of the lesion, whereas XPG cuts 3′. Then the excised DNA is replaced by a DNA-repair synthesis reaction that is catalyzed by DNA polymerase (Fig. 2b) [30].

The C19007T SNP is located on the exon of ERCC1 gene on chromosome 19q13.32 (Fig. 2a) [31]. It codes 118 Asparagine (Asn). The mutation does not change the amino acid. The ERCC1 protein has two main functional domains: a central domain and a helix-hairpin-helix (HhH2) domain (Fig. 2c). The central domain binds to DNA strand, whereas ERCC1 and XPF form heterodimer by HhH2 domain [32]. C19007T allele is located in the central domain. In a previous study, this allele was shown not to affect gene expression, but thought to possibly be a “passenger” that affects other polymorphisms and has a strong linkage disequilibrium with C19007CT, especially in Caucasians [32].

A total of 8 eligible studies, including 1169 subjects (425 non-responders and 744 responders) were identified and analyzed in this meta-analysis study. We found that C19007T polymorphism is not associated with the outcome of platinum-based chemotherapy in ovarian cancer using models comparison. However, an asymmetric funnel plot indicated the conflicting results of race-based comparisons and the legacy of the current study. In the subgroup analysis by race, a significant association was detected in ovarian cancer in homozygote and recessive models in our study. In terms of stratified analysis by race, we found this polymorphism had a trend of an increased treatment response in Asian populations in homozygote and recessive models comparisons. On the other hand, the studies of Caucasian population show conflicting results. For example, Steffensen [20] and Bösmüller [19] indicated that the OR was greater than 1, whereas, Smith [16], Steffensen [17] and Moxley [10] did not show significant difference. Moreover, even the same author, Steffensen K.D., had conflicting results in 2011 [20] and 2008 [17]. It suggests that the sample sizes of this study should be expanded. Compared with the other studies, the article of Steffensen K.D in 2011 may be more reliable because of the larger sample size (199 vs. 100).

This meta-analysis has several limitations. Firstly, detailed individual data are not available, and a more precise analysis should be conducted on other covariates,

### Table 3 Meta-analysis by Genetic Models for C19007T Polymorphisms

| SNP       | Genetic model     | Participants (%) | OR (95% CI) | Z   | p value | I²% | P_Het | Effect model | Begg's test p > | Egger's test p > | Harbord test p > |
|-----------|-------------------|------------------|-------------|-----|---------|-----|-------|--------------|----------------|----------------|------------------|
| ERCC1     | CC vs. CT + TT    | 1169 (50)        | 1.0 (0.75, 1.33) | 0  | 0.99  | 26.6 | 0.22 | Fixed        | 0.08           | 0.06           | 0.07             |
|           | TT vs. CT + CC    | 1169 (50)        | 1.16 (0.53, 2.55) | 0.38 | 0.7    | 72.5 | 0.001 | Random       | 0.81           | 0.83           | 0.91             |
| C19007T   | CC vs. CT         | 879 (39)         | 1.10 (0.81, 1.49) | 0.59 | 0.56  | 0.0  | 0.66 | Fixed        | 0.62           | 0.72           | 0.75             |
|           | CC vs. TT         | 656 (28)         | 0.85 (0.33, 2.22) | 0.33 | 0.74  | 72.4 | 0.001 | Random       | 0.81           | 0.86           | 0.56             |
|           | C vs. T           | 2338 (100)       | 1.07 (0.75, 1.52) | 0.38 | 0.7   | 66.9 | 0.004 | Random       | 0.03           | 0.06           | 0.07             |

ERCC1 excision repair cross complementation group 1

---

5' of the lesion, whereas XPG cuts 3'. Then the excised DNA is replaced by a DNA-repair synthesis reaction that is catalyzed by DNA polymerase (Fig. 2b) [30].

The C19007T SNP is located on the exon of ERCC1 gene on chromosome 19q13.32 (Fig. 2a) [31]. It codes 118 Asparagine (Asn). The mutation does not change the amino acid. The ERCC1 protein has two main functional domains: a central domain and a helix-hairpin-helix (HhH2) domain (Fig. 2c). The central domain binds to DNA strand, whereas ERCC1 and XPF form heterodimer by HhH2 domain [32]. C19007T allele is located in the central domain. In a previous study, this allele was shown not to affect gene expression, but thought to possibly be a “passenger” that affects other polymorphisms and has a strong linkage disequilibrium with C19007CT, especially in Caucasians [32].

A total of 8 eligible studies, including 1169 subjects (425 non-responders and 744 responders) were identified and analyzed in this meta-analysis study. We found that C19007T polymorphism is not associated with the outcome of platinum-based chemotherapy in ovarian cancer using models comparison. However, an asymmetric funnel plot indicated the conflicting results of race-based comparisons and the legacy of the current study. In the subgroup analysis by race, a significant association was detected in ovarian cancer in homozygote and recessive models in our study. In terms of stratified analysis by race, we found this polymorphism had a trend of an increased treatment response in Asian populations in homozygote and recessive models comparisons. On the other hand, the studies of Caucasian population show conflicting results. For example, Steffensen [20] and Bösmüller [19] indicated that the OR was greater than 1, whereas, Smith [16], Steffensen [17] and Moxley [10] did not show significant difference. Moreover, even the same author, Steffensen K.D., had conflicting results in 2011 [20] and 2008 [17]. It suggests that the sample sizes of this study should be expanded. Compared with the other studies, the article of Steffensen K.D in 2011 may be more reliable because of the larger sample size (199 vs. 100).

This meta-analysis has several limitations. Firstly, detailed individual data are not available, and a more precise analysis should be conducted on other covariates,
such as treatment dosage, patients’ status, and pathological stages. Secondly, the sample sizes of eight included studies are rather small and not adequate enough to detect the possible association between platinum-based chemotherapy effectiveness and ERCC1 polymorphisms. Thirdly, publication bias might be significant in our study. There are three points located at the higher-OR side and far from axes in the funnel plot (Fig. 3). It suggests the positive results are tending to be published, which may potentially influence the results of our meta-analysis.

**Conclusion**

In summary, this meta-analysis suggests that the C19007T polymorphism of the ERCC1 does not contribute to the platinum-based chemotherapy effectiveness in ovarian tumor. Future large-scale studies are still needed to confirm these findings.

**Abbreviations**

Asn: Asparagine; CI: Confidence intervals; CNKI: Chinese national knowledge infrastructure; ERCC1: Excision repair cross complementation group 1; HhH2: Helix-hairpin-helix; HWE: Hardy-Weinberg equilibrium; NER: Nucleotide excision repair; OR: Odds ratios; SNPs: Single nucleotide polymorphisms; WHO: World Health Organization

**Funding**

This work was supported by President Funding of Jinan Military General Hospital (No. 2012Q005) and PLA General Logistics Department of the Ministry of Health (No. 13QN030).

**Availability of data and materials**

For reprint and request for data supporting our findings, please contact the corresponding author.

**Authors’ contributions**

NT carried out the literature review, participated in the data extraction and drafted the manuscript. DL carried out the statistical analyses. YZ participated in the statistical analyses. NT participated in the design of the study. HL conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Consent for publication**

Not applicable.

**Ethics approval and consent to participate**

This study was approved by the Institutional Review Board of Jinan Military General Hospital.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Authors**

1. Reproductive Medicine Center, Jinan Military General Hospital, 25 Shifan Road, Tianqiao District, Jinan, Shandong Province 250031, China.
2. Department of Pain, Tianjin First Center Hospital, Nankai District, Tianjin 300192, China.

Received: 11 September 2015 Accepted: 16 May 2017

**Reference**

1. (WHO) WHO: Global cancer rates could increase by 50% to 15 million by 2020. 2003.
2. Yu JJ, Mu C, Lee KB, Okamoto A, Reed EL, Bostick-Bruton F, et al. A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mut Res/Mutation Res Genomics. 1997;382(1–2):13–20.
3. Yan L, Pei H, Yu C, Gui-ying W, Na W, Rong-miao Z. Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/a polymorphism of ERCC1: a meta-analysis. Biomarkers. 2014;19(2):128–34.
4. Gossage L, Madhusudan S. Current status of excision repair cross complementing group 1 (ERCC1) in cancer. Cancer Treat Rev. 2007;33(6):565–77.
5. Reed E, Larkins TL, Chau CH, Figg WD. DNA Repair: ERCC1. Nucleotide Excision Repair Platinum Resistance. 2014:333–49.
6. Deloia JA, Bhagwat NR, Darcy KM, Strange M, Tian C, Nuttall K, et al. Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum. Gynecol Oncol. 2012;126(3):448–54.
7. Rubatt JM, Darcy KM, Tian C, Muggia F, Dhir R, Armstrong DK, et al. Pretreatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic oncology group study. Gynecol Oncol. 2012;125(2):421–6.
8. Koc E, Caner V, Buyukpinarbasili N, Tepeli E, Turk NS, Ozan Cetin G, et al. The determination of relationship between "excision repair cross-complementing group 1" (ERCC1) gene T19007C and C8092A single nucleotide polymorphisms and clinicopathological parameters in non-small cell lung cancer. Mol Biol Rep. 2012;39(3):375–80.

9. De Castro G Jr, Pasini FS, Siqueira SA, Ferraz AR, Villar RC, Smitcovsky IM, et al. ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation. Oncol Rep. 2011;25(3):693–9.

10. Mosley KM, Benbrook DM, Queimado L, Zuna RE, Thompson D, McCumber M, et al. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer. Gynecol Oncol. 2013;130(2):377–82.

11. Qi BL, Li Y, Wang N, Zhou RM, Hu P, Kang S. Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy. Zhonghua Fu Chan Ke Za Zhi. 2013;48(11):847–52.

12. Bagos PG. Genetic model selection in genome-wide association studies: robust methods and the use of meta-analysis. Stat Appl Genet Mol Biol. 2013;12(3):285–308.

13. Begg CB, Berlin JA. Publication bias and dissemination of clinical research. J Natl Cancer Inst. 1989;81(2):107–15.

14. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.

15. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;25(20):3443–57.

16. Smith S, Su D, Rigault De La Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, et al. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol. 2007;25(33):5172–9.

17. Steffensen KD, Waldstrom M, Jeppesen U, Brandslund I, Jakobsen A. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer. Int J Gynecol Cancer. 2008;18(4):702–10.

18. Kang S, Woong J, Kim JW, Park N-H, Song Y-S, Kim SC, et al. Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Gynecol Oncol. 2009;112(3):320–4.

19. Bomsmüller H, Hächt-Petnehazy S, Webersinke G, Marschon R, Rothmeier F, Stummvoll W, et al. Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy. Virchows Arch. 2011;459(2):183–91.

20. Steffensen KD, Waldström M, Jakobsen A. DNA-repair ERCC1 Gene polymorphisms in epithelial ovarian cancer and relation to platinum resistance and survival. J Cancer Ther. 2011;2(2):140–2.

21. Shuying Y. ERCC1 gene polymorphisms and ovarian epithelial carcinoma patients with platinum chemotherapy sensitivity and prognostic relationship. Master degree. Shijiazhuang: Hebei medicine university; 2011.

22. Hayashino Y, Noguchi Y, Fukui T. Systematic evaluation and comparison of statistical tests for publication bias. Shijiazhuang: J Epidemiol. 2005;15(6):752:49–506.

23. Yoo JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F, et al. Comparison of two human ovarian carcinoma cell lines (A2780/CIP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol. 2000;16(3):555–60.

24. Arora S, Kothandapani A, Tillison K, Kalman-Maitese V, Patrick SM. Downregulation of XPF–ERCC1 enhances cisplatin efficacy in cancer cells. DNA Repair. 2010;9(7):745–53.

25. Luccardi G, Hartley JA, Hochhausser D. Importance of EGF/ERCC1 interaction following radiation-induced DNA damage. Clin Cancer Res. 2014;20(13):3496–506.

26. Allione A, Guarnera S, Russo A, Riccieri F, Purohit R, Pagnani A, et al. Inter-individual variation in nucleotide excision repair pathway is modulated by non-synonymous polymorphisms in ERCC4 and MBD4 genes. Mutat Res. 2013;751–752:249–55.

27. Slysikova J, Lorenzo Y, Karlén A, Carlens MH, Novosadova V, Blomhoff R, et al. Both genetic and dietary factors underlie individual differences in DNA damage levels and DNA repair capacity. DNA Repair (Amst). 2014;16:66–73.

28. Vilmar A, Sørensen JB. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer. 2009;64(2):131–9.

29. Voorder T, Metsalu A. Investigating gene expression profile of non-small cell lung cancer. Central European Journal of Medicine. 2011;6(5):608–15.

30. Masters JR, Koberle B. Curing metastatic cancer: lessons from testicular germ-cell tumours. Nat Rev Cancer. 2003;3(7):517–26.

31. Liu L, Li CH, Jin TF, Xu DY. Study on the ERCC1 gene polymorphism response to chemotherapy and prognosis of gastric cancer. Genet Mol Res. 2014;13(4):8722–8.

32. Tsolikov OV, Enzlin JH, Scharer OD, Ellenberger T. Crystal structure and DNA binding functions of ERCC1, a subunit of the DNA structure-specific endonuclease XPF-ERCC1. Proc Natl Acad Sci U S A. 2005;102(32):11236–41.

Submit your manuscript at www.biomedcentral.com/submit